Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 70Terminated 22Active not recruiting 19Withdrawn 10Recruiting 6Unknown 5Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2

Conditions

Multiple Myeloma 3Plasmablastic Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Interventional × ixazomib × Clear all
NCT02632396 2023-05-09

Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Emory University

Phase 1/2 Unknown
12 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03720041 2021-06-15

FiTNEss

University of Leeds

Phase 3 Unknown
740 enrolled
Plasma cell

Multiple Myeloma

NCT03669445 2020-07-30

IFM2018-01

University Hospital, Toulouse

Phase 2 Unknown
45 enrolled
Plasma cell

Multiple Myeloma

NCT03746652 2018-11-23

DARIA

Hellenic Society of Hematology

Phase 2 Unknown
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡